BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32777942)

  • 1. Immuno-oncology for esophageal cancer.
    Yamamoto S; Kato K
    Future Oncol; 2020 Nov; 16(32):2673-2681. PubMed ID: 32777942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for the treatment of advanced esophageal cancer.
    Harada K; Yamamoto S; Kato K
    Future Oncol; 2022 Jun; 18(18):2311-2319. PubMed ID: 35418242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab for the treatment of esophageal cancer.
    Yamamoto S; Kato K
    Expert Opin Biol Ther; 2020 Oct; 20(10):1143-1150. PubMed ID: 32620063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
    Kadono T; Yamamoto S; Kato K
    Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy.
    Ikeda G; Yamamoto S; Kato K
    Expert Opin Drug Saf; 2022 Jan; 21(1):55-65. PubMed ID: 34263677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
    Ikeda G; Miyakoshi J; Yamamoto S; Kato K
    Future Oncol; 2024 Apr; 20(11):665-677. PubMed ID: 38126175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
    Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [History and Perspective of Chemotherapy in Advanced Esophageal Cancer].
    Shiraishi K; Kato K
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
    Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
    Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab for the treatment of esophageal cancer.
    Mikuni H; Yamamoto S; Kato K
    Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy in Gastric Cancer.
    Högner A; Moehler M
    Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer.
    Hirose T; Yamamoto S; Kato K
    Therap Adv Gastroenterol; 2023; 16():17562848221148250. PubMed ID: 36644131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
    Harada K; Yamamoto S; Kato K
    Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
    Shah MA; Bennouna J; Doi T; Shen L; Kato K; Adenis A; Mamon HJ; Moehler M; Fu X; Cho BC; Bordia S; Bhagia P; Shih CS; Desai A; Enzinger P
    Future Oncol; 2021 Apr; 17(10):1143-1153. PubMed ID: 33533655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
    Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N
    BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.